GW Pharmaceuticals finds value in Cannabis

Email sent!Email could not be sent.Not sent: Recipient has unsubscribed

copy to mecopy to CRM

SciPro

This looks to be a huge step forward for epilepsy and GW Pharma - an exciting prospect for all those affected.

With GW Pharma the only UK based Pharmaceutical Company, researching the cannabis plant - could other pharma companies out there be missing a trick? Is there much potential in cannabis other than treatment related to Epilepsy?

{

An experimental cannabis-based drug from GW Pharmaceuticals has successfully treated children with a rare form of epilepsy, sending the company’s shares soaring and more than doubling its stock market value.
GW said a clinical trial showed its Epidiolex drug had significantly reduced seizures in patients with Dravet syndrome, a type of epilepsy for which there are currently no treatments approved in the US, compared to a placebo. In the trial of 120 patients, those taking Epidiolex saw a reduction of monthly convulsive seizures of 39% compared with 13% for a placebo, which GW said was highly statistically significant.